223 related articles for article (PubMed ID: 26860663)
1. Comparison of CT volumetric measurement with RECIST response in patients with lung cancer.
Hayes SA; Pietanza MC; O'Driscoll D; Zheng J; Moskowitz CS; Kris MG; Ginsberg MS
Eur J Radiol; 2016 Mar; 85(3):524-33. PubMed ID: 26860663
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for treatment response using dual-energy computed tomography in patients with advanced lung adenocarcinoma.
Hong SR; Hur J; Moon YW; Han K; Chang S; Kim JY; Im DJ; Suh YJ; Hong YJ; Lee HJ; Kim YJ; Choi BW
Eur J Radiol; 2018 Apr; 101():118-123. PubMed ID: 29571784
[TBL] [Abstract][Full Text] [Related]
3. Response criteria in solid tumors (PERCIST/RECIST) and SUV
Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
[TBL] [Abstract][Full Text] [Related]
4. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
5. TLG-S criteria are superior to both EORTC and PERCIST for predicting outcomes in patients with metastatic lung adenocarcinoma treated with erlotinib.
Ho KC; Fang YD; Chung HW; Liu YC; Chang JW; Hou MM; Yang CT; Cheng NM; Su TP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2155-2165. PubMed ID: 27260520
[TBL] [Abstract][Full Text] [Related]
6. Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy.
Sudarski S; Shi J; Schmid-Bindert G; Manegold C; Pilz LR; Zhou C; Schoenberg SO; Henzler T
J Thorac Oncol; 2015 Jan; 10(1):164-71. PubMed ID: 25247342
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
8. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
9. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
[TBL] [Abstract][Full Text] [Related]
10. Dynamic contrast-enhanced perfusion area detector CT for non-small cell lung cancer patients: Influence of mathematical models on early prediction capabilities for treatment response and recurrence after chemoradiotherapy.
Ohno Y; Koyama H; Fujisawa Y; Yoshikawa T; Seki S; Sugihara N; Sugimura K
Eur J Radiol; 2016 Jan; 85(1):176-186. PubMed ID: 26724663
[TBL] [Abstract][Full Text] [Related]
11. (99m)Tc-3PRGD 2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab.
Ma Q; Min K; Wang T; Chen B; Wen Q; Wang F; Ji T; Gao S
Ann Nucl Med; 2015 Jul; 29(6):519-27. PubMed ID: 25911312
[TBL] [Abstract][Full Text] [Related]
12. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L
Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209
[TBL] [Abstract][Full Text] [Related]
13. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
14. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
15. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
16. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
17. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients.
Wu TH; Hsiue EH; Lee JH; Lin CC; Liao WY; Ho CC; Shih JY; Yu CJ; Yang JC
Clin Lung Cancer; 2018 May; 19(3):e361-e372. PubMed ID: 29477365
[TBL] [Abstract][Full Text] [Related]
18. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience.
Fraioli F; Anzidei M; Zaccagna F; Mennini ML; Serra G; Gori B; Longo F; Catalano C; Passariello R
Radiology; 2011 May; 259(2):574-82. PubMed ID: 21357523
[TBL] [Abstract][Full Text] [Related]
19. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
[TBL] [Abstract][Full Text] [Related]
20. The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
Cirkel GA; Weeber F; Bins S; Gadellaa-van Hooijdonk CG; van Werkhoven E; Willems SM; van Stralen M; Veldhuis WB; Ubink I; Steeghs N; de Jonge MJ; Langenberg MH; Schellens JH; Sleijfer S; Lolkema MP; Voest EE
Ann Oncol; 2016 Aug; 27(8):1638-43. PubMed ID: 27234642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
